≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Drug-induced dystonia

Endpoint Browser PheWeb

DRUGADVERS_DYSTON

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — G24.0#

1 out of 7 registries used, show all original rules.

116

4. Check minimum number of events

None

116

5. Include endpoints

None

116

6. Filter based on genotype QC (FinnGen only)

115

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 816 453 361
Only index persons 739 416 323
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.02 0.01
Median age at first event (years)
Whole population 48.80 52.93 43.66
Only index persons 46.80 49.61 43.17

-FinnGen-

Key figures

All Female Male
Number of individuals 115 69 46
Unadjusted period prevalence (%) 0.02 0.02 0.02
Median age at first event (years) 46.83 48.15 44.84

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
116
Matched controls
1160
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G24.0
ICD-10 Finland
Drug-induced dystonia
+∞
167.4
116
*
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
26.9
70.4
61
46
N05AH03
ATC
olanzapine; systemic
20.4
55.7
53
46
N03AE01
ATC
clonazepam; systemic
19.9
45.8
41
31
N05AX08
ATC
risperidone; systemic
15.5
45.4
50
54
N05AX12
ATC
aripiprazole; systemic
20.5
44.7
39
28
N03AG01
ATC
valproic acid; systemic, rectal
15.7
39.9
41
39
F29
ICD-10 Finland
Unspecified nonorganic psychosis
16.9
37.7
36
30
N05AH04
ATC
quetiapine; oral
10.2
36.6
70
150
N04AA02
ATC
biperiden; systemic
42.7
32.6
40
14
N05BA01
ATC
diazepam; systemic, rectal
7.3
23.5
47
99
N05BA06
ATC
lorazepam; systemic, sublingual
11.0
22.5
27
31
G24.9
ICD-10 Finland
Dystonia, unspecified
224.9
19.1
19
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
6.5
18.1
37
78
N05BA04
ATC
oxazepam; oral
5.3
17.9
58
184
T36
ICD-10 Finland
Poisoning by systemic antibiotics
9.2
17.7
24
32
N05AH02
ATC
clozapine; systemic
22.3
17.4
25
14
F25.9
ICD-10 Finland
Schizoaffective disorder, unspecified
39.8
16.4
20
6
N06AB04
ATC
citalopram; systemic
5.1
16.2
49
145
N05AA02
ATC
levomepromazine; systemic
15.6
15.8
26
21
N05AD01
ATC
haloperidol; systemic
18.5
15.7
24
16
N06AB03
ATC
fluoxetine; oral
5.7
15.1
35
82
N05CD07
ATC
temazepam; oral
6.3
14.2
28
56
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
24.9
13.9
19
9
SPAT1254
SPAT
Administration of medicine
5.3
13.4
33
81
N06AX11
ATC
mirtazapine; oral
4.2
13.3
70
306
N05AB03
ATC
perphenazine; systemic, rectal
14.0
13.0
22
19
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
28.1
12.9
17
7
R56.8
ICD-10 Finland
Other and unspecified convulsions
10.7
12.8
25
29
P72
ICPC
Schizophrenia
17.0
12.8
20
14
N05AN01
ATC
lithium; oral
19.1
12.1
18
11
C07AA05
ATC
propranolol; systemic
3.9
11.3
47
171
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
10.9
11.1
21
23
N06AB06
ATC
sertraline; oral
4.6
10.9
31
85
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
14.0
10.8
18
15
N05BE01
ATC
buspirone; oral
12.4
10.8
19
18
F20.30
ICD-10 Finland
Undifferentiated schizophrenia continuous
21.3
10.6
15
8
G24.3
ICD-10 Finland
Spasmodic torticollis
36.2
10.6
13
*
N05AE05
ATC
lurasidone; oral
+∞
10.6
10
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.7
10.5
22
46
F20.9
ICD-10 Finland
Schizophrenia, unspecified
13.1
10.5
18
16
N07BB01
ATC
disulfiram; oral
9.8
10.1
20
24
F25.10
ICD-10 Finland
Schizoaffective syndrome, depressive type with only concomitant bipolar and schizophrenic symptoms
60.2
9.8
11
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.8
9.8
40
142
N05AC02
ATC
thioridazine; oral
33.1
9.6
12
*
N06AX16
ATC
venlafaxine; oral
4.0
9.6
34
109
F31.30
ICD-10 Finland
Bipolar disorder Depressive episode without somatic syndrome
24.1
9.6
13
6
N03AX09
ATC
lamotrigine; oral
8.3
9.6
21
30
N05AF03
ATC
chlorprothixene; systemic
11.5
9.4
17
17
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
5.1
9.3
22
51
A29
ICPC
General symptom/complaint other
4.4
8.9
26
72
N05AL01
ATC
sulpiride; systemic
18.1
8.8
13
8
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
22.0
8.7
12
6
N05AE04
ATC
ziprasidone; systemic
22.0
8.7
12
6
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
10.7
8.6
16
17
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
5.0
8.5
20
46
188
Kela drug reimbursment
Psychosis requiring demanding treatment
96.8
8.5
9
*
G24.8
ICD-10 Finland
Other dystonia
96.8
8.5
9
*
N05CF01
ATC
zopiclone; oral
3.2
8.3
50
223
SPAT1240
SPAT
Therapeutic discussion
4.1
8.1
26
77
F31.5
ICD-10 Finland
Bipolar affective disorder, current episode severe depression with psychotic symptoms
48.3
7.8
9
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
4.0
7.8
26
79
N03AX16
ATC
[U] pregabalin
3.2
7.8
40
162
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.9
7.7
26
80
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
14.7
7.6
12
9
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
6.5
7.5
19
34
F31.6
ICD-10 Finland
Bipolar affective disorder, current episode mixed
17.2
7.4
11
7
IGY02, ,
SPAT
32.2
7.3
9
*
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
32.2
7.3
9
*
SPAT1229
SPAT
Assessment of need for aid
8.4
7.2
15
20
IGY02
NOMESCO Finland
Psychiatric monitoring contact
9.2
7.1
14
17
IFA01
NOMESCO Finland
Psychiatric pharmacotherapy plan, not specified
18.0
6.9
10
6
F19.1
ICD-10 Finland
Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances, harmful use
42.6
6.8
8
*
AA400
NOMESCO Finland
Electroconvulsive therapy
42.6
6.8
8
*
F20.39
ICD-10 Finland
Undifferentiated schizophrenia UNS
42.6
6.8
8
*
F25.20
ICD-10 Finland
Schizoaffective syndrome, mixed type with only concomitant bipolar and schizophrenic symptoms
24.2
6.8
9
*
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
24.2
6.8
9
*
AA1AD
NOMESCO Finland
CT of head and brain
3.0
6.8
40
174
N06AX03
ATC
mianserin; oral
7.0
6.8
16
26
IGY99
NOMESCO Finland
Other psychiatric treatment contact
13.3
6.7
11
9
A06AD11
ATC
lactulose; oral
4.0
6.7
21
61
P99
ICPC
Psychological disorders other
8.2
6.6
14
19
F31.3
ICD-10 Finland
Bipolar affective disorder, current episode mild or moderate depression
73.7
6.5
7
*
F31.4
ICD-10 Finland
Bipolar affective disorder, current episode severe depression without psychotic symptoms
73.7
6.5
7
*
F39
ICD-10 Finland
Unspecified mood [affective] disorder
12.0
6.4
11
10
G72.8
ICD-10 Finland
Other specified myopathies
19.3
6.4
9
5
N05AA01
ATC
chlorpromazine; systemic, rectal
19.3
6.4
9
5
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
8.5
6.3
13
17
F19.21
ICD-10 Finland
Addiction caused by several drugs in combination and by other psychoactive substances currently independent but staying in a controlling environment
28.4
6.3
8
*
F11.22
ICD-10 Finland
Addiction-induced dependence is currently independent but uses substitute intermittent medication
+∞
6.3
6
*
A28
ICPC
Limited function/disability NOS
3.5
6.2
24
80
SPAT1301
SPAT
No procedures
2.7
6.1
45
218
SPAT1249
SPAT
Treatment-related counselling outside office
2.6
6.1
54
287
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.5
6.1
24
81
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
6.5
6.1
15
26
T90
ICPC
Diabetes non-insulin dependent
3.0
6.1
33
136
N05AF05
ATC
zuclopenthixol; systemic
16.1
6.0
9
6

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
17
13
15.08
10.55
13.3
28.5
1569.59
1413.15
nmol/l
0.20
17
13
57
248
3.55
10.30
3.9
2.9
7.47
8.33
mmol/l
0.49
48
214
20
40
5.83
9.98
3.6
1.3
—
—
—
0
0
16
13
14.05
9.70
7.3
17.3
833.69
809.62
nmol/l
0.04
16
13
49
201
3.49
9.59
5.4
4.2
—
—
—
0
0
76
410
3.48
9.47
8.2
6.2
1.21
1.21
mmol/l
0.15
70
348
19
25
8.86
9.09
3.7
1.3
—
—
—
0
0
21
48
5.12
9.04
4.3
1.3
—
—
—
0
0
21
50
4.91
8.62
4.3
1.3
—
—
—
0
0
21
50
4.91
8.62
4.3
1.3
—
—
—
0
0
49
213
3.25
8.57
2.9
3.2
90.42
79.63
mg/l
0.06
33
134
82
482
3.39
8.51
4.7
5.9
9.87
11.53
umol/l
0.90
77
459
59
290
3.11
8.30
2.5
2.3
48.44
56.57
u/l
0.73
54
269
50
228
3.10
7.96
3.3
3.6
14.88
10.17
mg/mmol
0.21
31
143
20
49
4.72
7.91
3.6
1.3
—
—
—
0
0
66
354
3.01
7.82
3.8
4.1
35.33
36.35
g/l
0.60
61
340
22
59
4.37
7.78
3.3
4.8
—
—
—
0
0
19
47
4.64
7.41
4.6
1.3
—
—
—
0
0
42
189
2.92
6.66
1.5
1.6
0.82
1.02
mg/l
0.32
31
145
12
13
10.14
6.46
1.3
1.1
—
—
—
0
0
34
139
3.05
6.37
1.9
1.4
1265.68
1245.58
nmol/l
0.04
28
110
60
341
2.57
5.87
2.2
1.7
93.37
101.69
pmol/l
0.65
36
166
94
692
2.89
4.99
3.9
3.7
11.34
9.53
mm/h
0.48
87
634
23
86
3.09
4.94
3.7
5.9
103.61
104.49
mmol/l
0.36
23
86
22
83
3.04
4.64
2.0
2.1
363.64
362.49
nmol/l
0.01
22
78
14
32
4.83
4.62
7.4
1.6
—
—
—
0
0
39
199
2.45
4.60
5.2
3.2
1.02
1.02
kg/l
—
9
21
68
452
2.22
4.21
6.6
5.8
—
—
—
0
0
59
375
2.17
4.04
21.8
10.5
1.11
1.12
inr
0.04
17
118
44
249
2.24
4.02
4.1
3.7
7.37
7.41
ph
—
7
47
70
482
2.14
3.83
6.4
5.4
0.55
0.56
e9/l
0.07
65
434
111
970
4.35
3.69
21.2
11.3
24.11
20.61
mg/l
0.64
94
733
71
498
2.10
3.63
11.0
5.8
0.17
0.19
e9/l
0.68
66
455
84
629
2.22
3.60
4.7
3.7
—
—
—
0
0
6
6
10.45
3.54
1.8
1.0
—
—
—
0
0
31
162
2.25
3.37
2.4
1.6
519.32
457.51
pmol/l
0.50
31
141
11
32
3.69
2.99
2.9
2.5
0.67
0.69
%
0.03
11
32
49
317
1.94
2.98
5.8
3.2
18.72
49.69
ng/l
1.06
34
196
48
309
1.94
2.96
3.2
3.1
30.06
61.32
e6/l
0.69
32
213
12
38
3.40
2.95
3.7
2.6
126.00
123.87
g/l
0.11
12
38
43
268
1.96
2.90
2.8
2.5
65.49
43.82
e6/l
0.19
30
204
10
28
3.81
2.86
8.2
3.3
—
—
—
0
0
21
100
2.34
2.80
1.5
1.3
—
—
—
0
0
24
122
2.22
2.76
2.3
2.3
0.81
2.68
e6/l
1.01
11
64
39
241
1.93
2.67
2.6
2.4
0.37
0.26
e6/l
0.15
28
178
10
31
3.43
2.59
4.0
2.8
25.19
23.61
mmol/l
—
10
31
10
31
3.43
2.59
1.6
1.6
—
—
—
0
0
20
97
2.28
2.56
2.1
1.5
—
—
—
0
0
23
119
2.16
2.53
1.6
1.9
111.29
97.53
ug/g
0.15
14
87
11
38
3.09
2.49
1.7
1.9
—
—
—
0
0
14
58
2.61
2.48
7.5
3.8
—
—
—
0
0
26
144
2.04
2.40
4.8
3.8
35.75
202.80
ng/l
0.90
16
105
11
40
2.93
2.35
10.0
7.4
—
—
—
0
0
37
237
1.82
2.22
4.4
2.7
—
—
—
0
0
60
447
1.71
2.12
4.6
3.2
0.00
0.00
estimate
—
10
88
9
32
2.96
2.05
3.4
4.6
—
—
—
0
0
56
413
1.69
2.03
9.5
9.4
0.00
0.00
e9/l
0.26
49
345
37
250
1.70
1.82
13.1
7.2
—
—
—
0
0
59
452
1.62
1.78
4.7
3.3
0.00
0.00
estimate
—
9
80
8
30
2.79
1.76
1.3
1.1
—
—
—
0
0
20
113
1.93
1.74
1.3
1.2
—
—
—
0
0
5
13
3.97
1.73
1.6
2.1
—
—
—
0
0
35
236
1.69
1.72
2.7
2.4
—
—
—
0
0
98
860
1.90
1.72
8.2
4.9
38.91
38.82
mmol/mol
0.03
93
806
103
920
2.07
1.69
6.3
3.9
5.99
5.84
mmol/l
0.65
96
850
30
196
1.72
1.65
4.5
3.2
—
—
—
0
0
25
375
0.58
1.65
2.8
2.5
—
—
—
0
0
58
450
1.58
1.61
6.4
4.5
0.00
0.00
estimate
—
9
85
10
44
2.39
1.60
3.1
6.2
1.43
1.62
%
—
10
44
10
44
2.39
1.60
3.2
6.2
0.79
0.73
%
—
10
44
13
65
2.13
1.55
1.9
2.3
1.70
6.11
ug/l
—
8
59
12
58
2.19
1.55
5.3
2.5
—
—
—
0
0
7
27
2.69
1.54
1.4
1.0
—
—
—
0
0
5
15
3.43
1.54
1.2
1.1
—
—
—
0
0
32
218
1.65
1.50
1.4
1.3
1.38
1.43
u/ml
—
10
64
13
68
2.03
1.40
2.2
2.6
—
—
—
0
0
10
47
2.23
1.38
2.2
4.9
26.81
24.95
mmol/l
—
10
47
14
77
1.93
1.32
4.1
3.8
1.60
1.00
%
—
5
25
5
18
2.85
1.30
4.4
4.7
11.32
20.07
mg/l
—
5
13
25
166
1.65
1.29
1.3
1.3
1.16
7.69
u/ml
—
8
70
14
78
1.90
1.27
7.1
4.8
—
—
—
0
0
11
56
2.07
1.27
1.5
1.2
—
—
—
0
0
6
26
2.38
1.20
12.7
6.1
—
—
—
0
0
18
116
1.65
1.04
2.0
1.8
—
—
—
0
0
103
954
1.71
1.01
5.7
4.1
4.38
4.71
mmol/l
2.91
97
886
73
633
1.41
0.99
5.0
3.3
—
—
—
0
0
30
223
1.47
0.95
1.9
1.9
—
—
—
0
0
32
242
1.45
0.93
5.2
3.3
0.00
0.00
estimate
—
9
84
19
129
1.57
0.90
2.5
1.9
11.90
14.09
umol/l
0.59
14
117
27
199
1.47
0.89
1.4
1.4
2.42
2.33
g/l
0.12
14
122
6
31
1.99
0.85
1.3
1.3
0.23
0.24
g/l
—
6
31
6
32
1.92
0.83
1.3
1.3
1.12
1.17
g/l
—
6
32
99
920
1.52
0.81
5.1
3.6
1.55
1.26
mmol/l
2.55
90
844
102
955
1.56
0.79
5.5
4.0
1.30
1.47
mmol/l
4.55
95
880
19
134
1.50
0.77
1.7
1.5
—
—
—
0
0
103
968
1.57
0.76
6.0
4.4
2.51
2.80
mmol/l
3.07
95
891
7
38
1.90
0.75
2.0
2.5
—
—
—
0
0
16
110
1.53
0.73
2.6
2.0
17.63
23.72
%
—
10
92
5
27
1.89
0.69
3.0
3.5
4.12
3.92
mmol/l
—
5
27
12
80
1.56
0.62
1.6
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.4
—
—
—
0
0
8
121
0.64
0.58
1.1
1.5
—
—
—
0
0
23
289
0.75
0.57
1.1
1.5
—
—
—
0
0
32
264
1.29
0.54
4.0
2.8
—
—
—
0
0
30
246
1.30
0.53
6.0
3.2
—
—
—
0
0
10
69
1.49
0.46
1.4
1.2
—
17.06
—
0
5
7
50
1.43
0.46
1.0
1.2
—
—
—
0
0
91
860
1.27
0.44
29.1
14.0
14.36
14.53
%
0.13
91
849
0
15
0.00
0.41
0.0
1.8
—
4.24
—
0
10
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
107
1037
1.41
0.37
21.8
10.7
—
—
—
0
0
12
92
1.34
0.33
1.6
1.4
—
—
—
0
0
7
51
1.40
0.32
1.3
2.2
—
—
—
0
0
8
64
1.27
0.28
2.8
1.4
—
—
—
0
0
6
83
0.71
0.25
1.3
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
173.48
—
0
10
0
12
0.00
0.21
0.0
1.3
—
186.97
—
0
12
0
12
0.00
0.21
0.0
1.0
—
0.94
—
0
5
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
20
176
1.16
0.19
1.9
1.7
—
—
—
0
0
33
359
0.89
0.19
2.1
1.8
—
—
—
0
0
6
80
0.74
0.16
8.3
3.3
—
—
—
0
0
8
76
1.06
0.07
1.5
1.3
—
—
—
0
0
10
89
1.14
0.07
1.4
1.3
—
—
—
0
0
9
102
0.87
0.06
1.3
1.1
—
—
—
0
0
28
272
1.04
0.02
3.8
2.1
—
—
—
0
0
11
103
1.08
0.02
1.6
1.9
—
—
—
0
0
13
127
1.03
0.00
1.6
1.7
—
—
—
0
0
15
145
1.04
0.00
1.7
1.4
—
596.00
—
0
30
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
5
55
0.91
0.00
1.0
1.8
1.57
1.10
g/l
—
5
48
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
587.63
—
0
8
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
12.10
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.4
—
3.74
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
35.73
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.3
—
70.13
—
0
8
0
8
0.00
-0.00
0.0
1.3
—
7.44
—
0
8

Mortality – FinRegistry

↥

Association

Association between endpoint DRUGADVERS_DYSTON and mortality.

Females

Parameter HR [95% CI] p-value
DRUGADVERS_DYSTON 2.337 [1.66, 3.29] < 0.001
Birth year 0.996 [0.99, 1.0] 0.327

During the follow-up period (1.1.1998 — 31.12.2019), 94 out of 404 females with DRUGADVERS_DYSTON died.

Males

Parameter HR [95% CI] p-value
DRUGADVERS_DYSTON 3.612 [2.33, 5.59] < 0.001
Birth year 0.987 [0.98, 1.0] 0.009

During the follow-up period (1.1.1998 — 31.12.2019), 88 out of 311 males with DRUGADVERS_DYSTON died.

Mortality risk

Mortality risk for people of age

years, who have DRUGADVERS_DYSTON.

N-year risk Females Males
1 0.25% 0.727%
5 1.384% 4.207%
10 3.357% 10.293%
15 6.468% 18.763%
20 11.315% 30.864%

Relationships between endpoints

↥

Index endpoint: DRUGADVERS_DYSTON – Drug-induced dystonia

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data